Adriamycin. A new anticancer drug with significant clinical activity.
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D055598:Chemical Phenomena; D002621:Chemistry; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007939:Leukemia L1210 / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D051379:Mice; D009101:Multiple Myeloma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D009447:Neuroblastoma / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy; D013280:Stomatitis / Q000139:chemically induced; D013736:Testicular Neoplasms / Q000188:drug therapy; D013964:Thyroid Neoplasms / Q000188:drug therapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D004338:Drug Combinations; D004317:Doxorubicin